Q-omics provides the consensus-scored SNX24 profile across patient tissues and cancer cell-line models. SNX24 expression is associated with patient survival in 29 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, SNX24 is differentially expressed in 11, with the highest sampling consensus in COAD. Additionally, SNX24 RNA expression shows 19,869 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight BLCA, COAD, and ACC as cancer lineages where SNX24 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SNX24 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SNX24 survival associations across molecular data types. SNX24 RNA expression shows survival associations in the most cancer types (29), followed by mutation status (4) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SNX24 RNA expression–survival associations across cancer types. High SNX24 expression shows unfavorable associations in BLCA, HNSC, LGG, ACC and LIHC, but favorable associations in KIRC. The BLCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify BLCA as the clearest survival context for SNX24 RNA expression.
This table summarizes SNX24 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 4. The strongest signals are observed in COAD for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for SNX24. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SNX24 shows lower tumor expression in COAD, LUAD and READ and higher tumor expression in KICH, LIHC and THCA. The COAD box plot shows higher SNX24 RNA expression in normal versus tumor tissue (log2 FC = −1.559, t-test p < 0.001).
This table shows molecular features associated with SNX24 in patient tissues and cancer cell lines. In patient samples, SNX24 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, SNX24 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in URINARY_TRACT, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and LARGE_INTESTINE.
